A Pilot Study of ctDNA-Guided Immune Checkpoint Inhibitor Duration in Patients With Advanced Melanoma.

This is a phase II pilot study evaluating the use of circulating tumor DNA (ctDNA) to guide the optimal duration of standard of care immune checkpoint inhibitor (ICI) therapy in patients with unresectable and/or metastatic melanoma who have radiographic evidence of disease control and/or response to treatment.

Sex

All

Minimum age

18 Years

Maximum age

90 Years

Inclusion Criteria:

1. Age \> 18 with any subtype of unresectable stage III or stage IV melanoma treated with anti-PD-1-based ICI which includes both anti-PD-1 monotherapy and dual checkpoint inhibitor regimens such as ipilimumab plus nivolumab and nivolumab plus relatlimab.

   Disease control after at least 6-12 months of anti-PD-1-based ICI defined as a radiographic RECIST CR, PR, or SD and planned for at least 1 year of treatment

   OR

   Development of an irAE(s) on an anti-PD-1-based regimen requiring treatment interruption and immunosuppression where the investigator is considering treatment discontinuation. Patients must have a radiographic RECIST PR or CR at the treatment duration decision time point.
2. Any line of therapy, with the exception of adjuvant therapy.
3. Ability to understand and the willingness to sign a written informed consent document.
4. Patients with brain metastasis may be included only if there was also presence of extracranial disease.
5. ECOG performance status 0-2.

Exclusion Criteria:

1. Participants who are receiving investigational therapies.
2. Inadequate tumor quantity or quality to conduct initial Signatera ctDNA testing.
3. Intracranial-only metastatic melanoma.
4. Patients with best response of progressive disease at time of screening.
5. Patients who have had their melanoma completely surgically resected such that response to immunotherapy is no longer evaluable.
6. Patients who are unwilling to continue or stop ICI therapy using ctDNA guidance in combination with imaging response.
7. History of a life-threatening or severe irAE that would make ICI rechallenge unsafe. These cases will be discussed with the Principal Investigator.
8. Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study.

• BACKGROUNDAmiot M, Mortier L, Dalle S, Dereure O, Dalac S, Dutriaux C, Leccia MT, Maubec E, Arnault JP, Brunet-Possenti F, De Quatrebarbes J, Granel-Brocard F, Gaudy-Marqueste C, Pages C, Stoebner PE, Saiag P, Lesimple T, Dupuy A, Legoupil D, Montaudie H, Oriano B, Lebbe C, Porcher R. When to stop immunotherapy for advanced melanoma: the emulated target trials. EClinicalMedicine. 2024 Dec 4;78:102960. doi: 10.1016/j.eclinm.2024.102960. eCollection 2024 Dec. PMID 39717261
• BACKGROUNDJansen YJL, Rozeman EA, Mason R, Goldinger SM, Geukes Foppen MH, Hoejberg L, Schmidt H, van Thienen JV, Haanen JBAG, Tiainen L, Svane IM, Makela S, Seremet T, Arance A, Dummer R, Bastholt L, Nyakas M, Straume O, Menzies AM, Long GV, Atkinson V, Blank CU, Neyns B. Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. Ann Oncol. 2019 Jul 1;30(7):1154-1161. doi: 10.1093/annonc/mdz110. PMID 30923820
• BACKGROUNDRobert C, Ribas A, Hamid O, Daud A, Wolchok JD, Joshua AM, Hwu WJ, Weber JS, Gangadhar TC, Joseph RW, Dronca R, Patnaik A, Zarour H, Kefford R, Hersey P, Zhang J, Anderson J, Diede SJ, Ebbinghaus S, Hodi FS. Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. J Clin Oncol. 2018 Jun 10;36(17):1668-1674. doi: 10.1200/JCO.2017.75.6270. Epub 2017 Dec 28. PMID 29283791
• BACKGROUNDSchroeder C, Gatidis S, Kelemen O, Schutz L, Bonzheim I, Muyas F, Martus P, Admard J, Armeanu-Ebinger S, Guckel B, Kustner T, Garbe C, Flatz L, Pfannenberg C, Ossowski S, Forschner A. Tumour-informed liquid biopsies to monitor advanced melanoma patients under immune checkpoint inhibition. Nat Commun. 2024 Oct 9;15(1):8750. doi: 10.1038/s41467-024-52923-0. PMID 39384805
• BACKGROUNDWarburton L, Reid A, Amanuel B, Calapre L, Millward M, Gray E. Detectable ctDNA at the time of treatment cessation of ipilimumab and nivolumab for toxicity predicts disease progression in advanced melanoma patients. Front Oncol. 2023 Dec 19;13:1280730. doi: 10.3389/fonc.2023.1280730. eCollection 2023.